logo
Share SHARE
FONT-SIZE Plus   Neg

TONIX Closes PK Study On New Formulation Of TNX-102 For Fibromyalgia

Tonix Pharmaceuticals Holding Corp (TNXP.OB), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system or "CNS", said that it completed a pharmacokinetic or PK study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome or "FM".

The company noted that the study results support further development of TNX-102 as a product that can potentially deliver benefits similar to those observed in FM patients treated with very low dose cyclobenzaprine in the Company's dose-escalating Phase 2a study.

TONIX said that it is developing new formulations of cyclobenzaprine that are designed for bedtime use. The Company is investigating different technologies to improve the absorption of cyclobenzaprine. The technology applied in this study involves a mixture of cyclobenzaprine and lipids that the Company obtained from Lipocine, Inc. and is designated TNX-102 2.4 mg promicellar gelatin capsules, or gelcaps.

TONIX said that it is on track to initiate a pivotal efficacy study with the final formulation of TNX-102 in the first quarter of 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cable-cutters have now one more reason to do so as live television streaming will be available on YouTube TV in 14 more markets in the U.S. Facebook Chief Operating Officer Sheryl Sandberg has donated nearly $100 million in Facebook shares to charity. This is her second charitable donation within a year. A document was filed on Thursday with the Security and Exchange Commission, which shows that Sandberg transferred shares to a special fund she uses for charitable donations. Ford Motor Co.'s new CEO Jim Hackett has taken a more cautious approach to the automaker's plans for rolling out autonomous vehicles. Ford is currently undertaking a 100-day review of its operations and Hackett indicated at delays to the company's plans to launch a fully-autonomous vehicle by 2021.
comments powered by Disqus
Follow RTT